- Home
- DAVE vs COLL Comparison
DAVE vs COLL Comparison
Compare DAVE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- COLL
- Stock Information
- Founded
- DAVE 2017
- COLL 2002
- Country
- DAVE United States
- COLL United States
- Employees
- DAVE N/A
- COLL N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- COLL Health Care
- Exchange
- DAVE Nasdaq
- COLL Nasdaq
- Market Cap
- DAVE 1.2B
- COLL 1.0B
- IPO Year
- DAVE N/A
- COLL 2015
- Fundamental
- Price
- DAVE $100.90
- COLL $29.13
- Analyst Decision
- DAVE Strong Buy
- COLL Strong Buy
- Analyst Count
- DAVE 7
- COLL 5
- Target Price
- DAVE $99.86
- COLL $43.60
- AVG Volume (30 Days)
- DAVE 459.9K
- COLL 294.2K
- Earning Date
- DAVE 03-03-2025
- COLL 02-27-2025
- Dividend Yield
- DAVE N/A
- COLL N/A
- EPS Growth
- DAVE N/A
- COLL 757.11
- EPS
- DAVE 3.12
- COLL 2.16
- Revenue
- DAVE $319,355,000.00
- COLL $599,245,000.00
- Revenue This Year
- DAVE $34.72
- COLL $13.25
- Revenue Next Year
- DAVE $19.38
- COLL $17.67
- P/E Ratio
- DAVE $32.34
- COLL $13.47
- Revenue Growth
- DAVE 30.00
- COLL 9.62
- 52 Week Low
- DAVE $20.50
- COLL $28.39
- 52 Week High
- DAVE $125.00
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- DAVE 49.49
- COLL 37.61
- Support Level
- DAVE $101.00
- COLL $29.39
- Resistance Level
- DAVE $125.00
- COLL $30.39
- Average True Range (ATR)
- DAVE 8.61
- COLL 1.00
- MACD
- DAVE -0.18
- COLL -0.24
- Stochastic Oscillator
- DAVE 37.19
- COLL 11.04
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.